INTRODUCTION
The technique of producing antibody-secreting hybridomas (K6hler & Milstein; 1975) has opened up possibilities of obtaining pure specific antibodies to use for the examination of antigens and to use as diagnostic reagents. This method is of particular value where an antigen is difficult to purify or poorly immunogenic; it also permits the 'dissection' of the antibody response to a complex mixture of antigens where purification of a specific antigen has proved impossible.
Until recently, purified hepatitis B virus (HBV) antigens used in the development of diagnostic assays necessarily had been isolated from human serum or liver tissue. The e antigen (HBeAg) associated with hepatitis B is relatively difficult to purify from serum and displays considerable physical heterogeneity (Tedder & Bull, 1979) , existing in serum partly as a free entity and partly as a complex with IgG (Takahashi et al., 1978) . The resulting difficulty in isolation of HBeAg has hindered the production of high-titre animal antisera. The relationship between the core antigen (HBcAg) and HBeAg demonstrated initially by Budkowska et al. (1979) suggested an alternative source of HBeAg for this purpose. They showed that HBcAg isolated from liver tissue could be converted to HBeAg by treatment with mild detergents and proteolytic enzymes. More recently, it has been shown that the e determinants are carried on the polypeptide of a genetically engineered core antigen expressed in Escherichia coli, unequivocally demonstrating the relationship between these two antigens and a single polypeptide (MacKay et al., 1981) .
Polyclonal stimulation and transformation of peripheral blood lymphocytes from an antiHBe-positive hepatitis B surface antigen (HBsAg) carrier have resulted in limited production in vitro of anti-HBe (Furuya et al., 1982) . The level of antibody secretion was low and the clones were reported as being unstable. Using conventional techniques in mice, Imai et al. (1982) reported the production of monoclonal antibodies to HBeAg using highly purified serum HBeAg to immunize the animals. In view of the difficulty of producing sufficient purified serum HBeAg, we have used the antigen produced by degradation of HBcAg. In this paper we report the use of HBeAg derived from highly purified liver HBcAg to immunize mice prior to producing anti-HBe-secreting hybridomas. The method used for the detection of antibodysecreting hybridomas, the subsequent characterization of the monoclonal antibodies and their use in a diagnostic assay are described.
METHODS
HBcAg. Core antigen was prepared from the postmortem liver of an immunosuppressed hepatitis B carrier. Washed liver tissue was extracted by grinding with sand in distilled water. The extract was clarified and then pelleted (25000 r.p.m., T50 rotor, 2 h; L2 Beckman centrifuge). The pellet was further purified by isopycnic banding of the pelleted material on a self-forming CsCI density gradient (40000 r.p.m., SW50 rotor, 72 h; L2 Beckman centrifuge). Fractions containing HBcAg (density 1.34 g/ml) were detected by a sandwich radioimmunoassay (RIA), pooled, dialysed against 20 mM-Tris-buffered saline (TBS) and stored at 4 °C.
To denature HBcAg to HBeAg, 0-2~0 2-mercaptoethanol (2-ME; BDH) and 0.2~ SDS (BDH) were mixed in equal proportions. This mixture was then added to an equal volume of purified HBcAg and incubated at 37 °C for 2 h. The resulting preparations gave a pronounced line of identity with serum HBeAg in gel and showed no reactivity for HBcAg.
The gene for HBcAg had previously been cloned in pBR322 and expressed in E. coli (Stahl et al., 1982) . Core antigen from a bacterial cell lysate, a generous gift from Biogen S.A. (Geneva, Switzerland) was purified to homogeneity as judged by SDS-polyacrylamide gel electrophoresis and then stored at -20 °C. Part of this product was fractionated on CsC1 isopycnic gradients, part subjected to electron microscopy and part used for degradation experiments.
Gel immunodiffusion (ID). Sera, antigens and ascitic fluids containing monoclonal antibodies were examined by ID for HBcAg, HBeAg and anti-HBe as described previously (Tedder, 1978) .
Serum samples and fractions. Samples of blood were allowed to clot. After centrifugation, the serum was removed and stored at -20 °C before use. Standard sera containing either HBeAg or anti-HBe were taken from carriers of HBsAg. HBeAg and anti-HBe reactivity was demonstrated by ID and by solid-phase polyclonal RIA (Tedder et al., 1980) . Normal human serum (NHS) negative by RIA for all HBV markers was obtained from blood donors with a history of malaria. Anti-HBc IgG was prepared from HBsAg-carrier serum containing HBeAg, and antiHBe lgG from HBsAg-carrier serum containing anti-HBe by ion-exchange chromatography as previously described (Tedder et al., 1980) .
Tests for HBVmarkers. HBsAg, anti-HBs, anti-HBc, HBeAg and anti-HBe were detected in solid-phase RIA as previously described (Tedder et al., 1980) . Animals. BALB/c mice (Bantin and Kingman Ltd., Aldbrough, Yorks., U.K.) and SJL/Olac mice (Olac 1976 Ltd., Bicester, Oxon., U.K.) were immunized prior to raising hybridomas. Female F1 crosses (BALB/c x SJL) were used for subsequent intraperitoneal (i.p.) propagation of hybridomas secreting anti-HBe.
Immunization. BALB/c and SJL/Olac mice were injected subcutaneously in the neck with HBeAg derived from human liver HBcAg mixed with an equal volume of Freund's complete adjuvant. Forty-two and 92 days later, further doses of HBeAg in phosphate-buffered saline (PBS) were given i.p. Twenty-one days after the third dose, HBeAg diluted in PBS was injected intravenously. Three days later the mice were killed with CO2 and the spleens removed aseptically for fusion with HRPT' myeloma cells (a subclone JK, derived from P3-X63-Ag8.653; Kearney et al., 1979) as previously described (Tedder et aL, 1982) .
RIA capture assay for anti-HBe screening of hybridomas. Fourteen days after fusion, supernatant fluids (SNF) from viable hybridoma cultures were tested for anti-HBe activity. Round-bottom polystyrene wells (Removawell, Dynatech) were coated with 100 ~tl of a 1:400 dilution in Tris buffer (0.02 M pH 7.6 with HC1, containing 0.1% sodium azide) of the IgG fraction of rabbit anti-mouse IgG (anti-whole molecule, Miles Laboratories). After 3 days at room temperature, the wells were washed and quenched for 1 h with 0.5~ bovine serum albumin in Tris buffer (Tris-BSA). The wells were then sealed and stored moist at 4 °C.
Just before use, the contents of wells were aspirated. One-hundred ~tl of a 1 : 10 dilution in Tris-BSA of SNF from viable hybridomas was added to the wells and incubated at 37 °C for 4 h. After washing, 100 ktl of a 1:400 dilution in Tris-BSA of HBcAg-derived HBeAg were added and left overnight at room temperature. The following morning the wells were washed again and 100 p.1 of 125i_labelled human anti-HBe IgG (approx. 60 nCi diluted in Tris buffer containing 2% BSA and 20~ NHS) was added and left for a further 4 h at 37 °C. Finally, the wells were washed and bound radioactivity was measured. SNF containing anti-HBe gave an increased binding of 12Si.anti.HBe. Anti-HBe-secreting hybridomas were subsequently re-tested by the same capture assay using both serum HBeAg and the HBeAg derived from HBcAg. Those hybridomas in which anti-HBe was detected using both serum and liver-derived HBeAg were chosen for subsequent cloning and expansion.
Production of ascitic fluid. Female mice, aged 12 to 20 weeks, were primed i.p. with 0-5 ml Pristane (Aldrich Chemical Company). BALB/c mice were used for clones arising from the BALB/c fusion and BALB/c x SJL mice used for clones arising from the SJL fusion. One to 4 weeks after priming with Pristane, 50 mg/kg of cyclophosphamide was injected i.p, followed 24 h later by cloned hybridoma cells (1 × 107 cells per mouse). The ascitic fluid was aspirated l to 3 weeks later, separated from cells and stored at -20 °C.
Investigations of the monoclonal antibodies
Serum protein electrophoresis (SPE) . Ascitic fluid from each clone was tested for the presence of a monoclonal protein band by SPE (Paragon Electrophoresis System, Beckman). This commercially available kit allowed the rapid examination of fluids for monoclonal protein bands. Used in accordance with the manufacturer's recommendations it readily and conveniently identified those ascitic fluids containing high levels of monoclonal immunoglobulin. Previous experience had shown that it was difficult to prepare purified reagents from ascitic fluid in the absence of such a band.
Purification and radioiodination. The immunoglobulin fraction of ascitic fluid was purified by chromatography on DE52 (Whatman) using stepwise elutions with 10, 30 and 60 raM-phosphate buffers pH 8.0 (Tedder et al., 1982) . It was labelled with 125I (Amersham International) using methods described previously ('redder et al., 1982) to an activity of approx, l mCi per 30 ~tg protein.
Cross-competition assays. Removawells were coated with 100 ~tl of a dilution in Tris buffer of a 40~o ammonium sulphate precipitate of the globulin fraction from a high-titre human anti-HBe-positive serum. After 3 days the wells were washed and quenched with Tris-BSA. One hundred/al of a 1 in 50 dilution of HBeAg-positive serum in Tris-BSA containing 10~ NHS was added to the wells and left overnight at room temperature. The following day, the wells were washed and 5 ~tg of purified immunoglobulin from each individual monoclonal hybridoma in 50 ~tl of Tris-BSA was added separately to replicate wells to which 125I-labelled monoclonal antibodies (25 nCi in 50 ~tl of Tris buffer containing 2~ BSA and 20~ NHS) had been added at the same time. The mixtures of labelled and unlabelled fractions were left in the wells overnight at room temperature. After washing, the bound radioactivity was measured and expressed as the percentage of the maximum label-binding occurring when no competing unlabelled antibody had been added.
Solid-phase RIA using monoelonal anti-HBe. Six clones were chosen for coating the solid phase on the basis of their high levels of secreted monoclonal antibody demonstrated by SPE. The globulin fraction was precipitated separately from each fluid with 40~ saturated ammonium sulphate. Removawells were coated with an optimum dilution of globulin (between 1 : 300 and 1 : 1000) which had been determined by previous titration experiments for each monoclonal antibody. After 72 h at room temperature the wells were quenched with Tris-BSA. One-hundred lal of HBeAg-positive serum, diluted to 1 in 50 in Tris-BSA containing 10 ~ NHS, was added to wells coated with each of the six clones. The following morning, the wells were washed and 100 lal of a25I-Ig from each of the hybridomas was added separately to replicates of the wells coated with each of the individual clones. The wells were washed after 2 h incubation at 37 °C and the amount of bound radioactivity measured and expressed as a percentage of the total label added.
An optimum combination of antibody reagents was then used to test the diagnostic sera for HBeAg. Reactivity was considered specific for HBeAg only if it was neutralized by the addition of human high-titre anti-HBe. In addition, sera were tested for anti-HBe by assaying for neutralization of a small quantity of HBeAg added individually to each serum under test.
Generation of HBeAg from HBcAg. HBcAg both from liver and from E. coli was incubated for various times under various conditions to determine factors influencing the rate of release of HBeAg.
Fractionation of sera containing HBeAg. Serum containing HBeAg was fractionated under non-dissociating conditions by downward flow in Tris-saline over Sephacryl S-300 (Pharmacia) in a 50 x 2.5 cm column. Serum was also fractionated under dissociating conditions in 3 M-KCNS as previously described (Tedder & Bull, 1979) . Fractions containing dissociated HBeAg were sized by downward-flow fractionation on a 50 x 2.5 cm column packed with Sephadex G-100 (Pharmacia) which had been previously calibrated with protein markers of known molecular weight.
RESULTS
Attempts to produce hybridomas secreting anti-HBe following immunization with HBeAgenriched serum fractions were unsuccessful. Mice immunized with this material produced barely detectable levels of anti-HBe and fusions did not result in hybridomas secreting anti-HBe. As a result, core-derived HBeAg was used as an alternative antigen. The splenocytes from BALB/c and SJL/Olac mice which had received the liver-derived HBeAg were separately fused to JK Ag8.653 cells.
Six of the 400 hybridomas from the BALB/c mouse and 44 of a similar number from the SJL mouse were initially considered reactive for anti-HBe using the HBcAg-derived HBeAg in the capture assay. After further growth and re-testing separately with serum HBeAg and liverderived HBeAg, one hybridoma from the BALB/c fusion and 17 from the SJL fusion remained reactive for anti-HBe. Fifteen hybridoma cultures, selected from wells containing less than four colonies, which gave high reactivity with both types of HBeAg in the capture assay were chosen for further studies. These were cloned by limiting dilution 14 days after fusion. Only wells containing a colony that had arisen from a single cell after cloning were further tested for anti-HBe production by the capture assay. Twelve hybridomas, including the only one from the BALB/c fusion, were successfully cloned in this way and continued to secrete anti-HBe (Table 1) .
Single anti-HBe-secreting daughter clones from each of the 12 hybridoma parents (identified as el to el2 inclusive) were chosen for expansion. These were propagated in culture and then injected i.p. into either BALB/c or BALB/c x SJL mice. Ascitic fluids containing anti-HBe were obtained from 11 of the 12 clones. Monoclonal protein bands were detected by SPE in 10 of 11 ascitic fluids (ell contained no visible band). Immunoglobulin was prepared from all ascitic fluids, including e11, by fractionation on DE52, and the anti-HBe activity in each fraction assayed by capture RIA.
No monoclonal anti-HBe, either as purified immunoglobulin or as whole ascitic fluid, produced a visible line in ID when tested singly or as mixtures, although some clones, in particular e2, e3, e4, e7, elO, ell and e12, appeared to inhibit partially the formation of lines in ID by the control sera. A similar phenomenon is encountered in ID with certain human sera containing anti-HBe which can be detected by solid-phase immunoassays. These sera, although not precipitating in ID by themselves, will interfere greatly with the formation of e precipitins by other sera (Tedder, 1978) .
Cross-competition assay
Since it proved impossible to investigate the degree of similarity between the antigenic specificities recognized with each clone by ID experiments as described by Imai et al. (1982) , cross-competition studies were undertaken. Preparations of purified immunoglobulin from each clone were tested at approximately a 1000-fold molar excess for their ability to inhibit the binding of labelled monoclonal immunoglobulin to solid-phase HBeAg. Apart from ell, which failed to exhibit any specific binding, all the unlabelled clones effectively inhibited the binding of labels made from their own immunoglobulin. Broadly speaking, the patterns of reactivity fell into two groups, subsequently called e-a and e-ft. Within each group there was major crossinhibition but between the two groups there was only minor or no cross-inhibition (Table 2) . A single clone, el2, appeared to recognize a site different from the others. Single monoclonal antibodies were inefficient in blocking the binding of human polyclonal anti-HBe to immobilized HBeAg. Their efficiency could have been influenced by avidity alone. But when pools of antibody of e-a or e-fl specificity were tested singly or as a mixture, more effective inhibition was achieved. Thus, although an e-a antibody pool alone reduced 12sI-labelled polyclonal anti-HBe binding by 31 ~, and an e-fl antibody pool alone by 5 3 ~, a mixture of both reduced the binding by nearly 65 ~.
Solid-phase RIA for detection of HBeAg and anti-HBe
Serum HBeAg was detected in solid-phase assays using different combinations of e-a and e-fl monoclonal antibodies. The clones used for these experiments were selected on the basis of a good yield of monoclonal antibody in ascites as measured by SPE. Only three were chosen from either of the e-a or e-fl groups of monoclonal antibodies. In terms of their ability to detect serum HBeAg, once again the clones tested appeared to be divisible into the same two distinct groups. When e7 or elO (e-a) were on the solid phase, a high proportion of 12SI-labelled e6, e8 or e9 (e-fl), but not of e7 or elO (e-a) was bound. The converse applied for assays using solid-phase e6, e8 or e9. Thus, only heterologous assays containing antibodies from both of the e-a and e-fl groups successfully detected HBeAg (Table 3) . The clone el2 which appeared to recognize a unique site displayed the same pattern of reactivity in RIA as e7 and elO. For this reason, it was included in the e-a group.
Assays for the detection of HBeAg were developed. These served both to test the specificity of the monoclonal antibodies and to investigate their usefulness in diagnostic tests. Antibodies of the e-fl group were used on the solid phase as they were, weight for weight of immunoglobulin, about three times as efficient as those of the e-a group. In order to determine the sensitivity of this solid-phase RIA for HBeAg, a human serum containing HBeAg, positive both in ID and conventional polyclonal assay, was serially diluted in NHS. The dilutions were incubated * A number of RIAs were constructed using various combinations of different monoclonal antibodies for coating the solid phase and for the preparation of ~ 25i_labelled anti-HBe labels. For each combination 100 ktl of a 1 in 100 dilution in NHS of a serum containing HBeAg was incubated overnight at room temperature in the coated wells. The wells were then washed and 125i_anti_HB e was added for 4 h at room temperature. After this, the wells were washed a final time and the percentage binding of label measured for each combination.
t Identity of epitope recognized. :~ r,rr, Not tested. § Binding of 12SI-anti-HBe in absence of HBeAg. * One-hundred ~tl of a serum containing HBeAg, or dilutions in NHS, were incubated overnight in a solid phase coated with either monoclonal or polyclonal human anti-HBe globulin. After washing, 1251-anti-HBe, either monoclonal or human polyclonal, was added and incubated at room temperature for 3 h. The binding of radiolabel was determined for each dilution of serum in both the monoclonal assay and in the polyclonal assay.
t Monoclonal antibodies e6 (fl) and e9 (fl) were coated on the solid phase, with 125I-e10 (~t) used as the tracer.
:~Polyclonal human anti-HBe globulin was coated on the solid phase and polyclonal human anti-HBe IgG used as the tracer.
§ rcr, Not tested.
overnight in the solid phase and after washing, the labelled anti-HBe was added for 3 h at room temperature. The maximal levels of binding seen with the higher concentrations of HBeAg (Table 4) suggested that these reagents were of high avidity and that the assay would be able to detect low levels of antigen. This was the case, with the endpoint dilutions of this serum giving a higher level of label binding in the monoclonal RIA than in the conventional polyclonal RIA.
To investigate further the specificity of these antibodies, the monoclonal solid-phase RIA [e6 and e9 (e-fl) on the solid phase and radiolabelled elO (e-00 or e2 (e-o0] was used to detect HBeAg in 100 routine clinical sera by a two-site sequential RIA as described above. In addition, antiHBe was detected in the same 100 sera by the addition of low levels of HBeAg from a serum source to the test sera and by measuring their ability to neutralize the added HBeAg reactivity in the monoclone-based assay. The correlation between the assay based on monoclonal reagents and that based on polyclonal reagents was extremely good (Table 5) .
Relationship of HBeAg to HBcAg
Having ascertained that a combination of one monoclonal antibody from each group appeared to detect by RIA a reactivity which was identical with serum HBeAg, experiments were performed to examine the relationship between these HBeAg reactivities and HBcAg. * Sera were tested in parallel for HBeAg and anti-HBe using solid-phase RIAs based either on human polyclonal reagents or on mouse monoclonal reagents. For the detection of HBeAg, sera were incubated overnight in a coated solid phase. The subsequent binding of l ZSl-anti-HBe was measured. For the detection of anti-HBe, sera were mixed with an equal volume of a high dilution in NHS of an HBeAg-positive serum, and then assayed as before. Sera were considered to contain significant levels of anti-HBe if the added HBeAg could no longer be detected. Table 6 . Release of HBeAg reactivity from HBcAg expressed in E. coli* Binding of t25I-anti-HBe (%) at: Confirmation that the reactivity detected by monoclonal reagents was carried on the core polypeptide was demonstrated by the conversion of particulate core antigen produced in E. coli to HBeAg by detergent treatments similar to those which had been found effective for the liver core antigen.
Firstly, the time course of conversion of HBcAg (both liver and E. coli) to HBeAg was examined. No enhancement was found with 2-ME; indeed, HBeAg reactivity measured by monoclonal RIA appeared partially sensitive to reduction (Table 6 ). The addition of 100 ~tM-phenylmethylsulphonyl fluoride (PMSF; Sigma) did not inhibit the conversion, which seemed to occur rapidly following the addition of SDS alone. No increased generation of reactivity was seen after prolongation of incubation at 37 °C with SDS beyond 2 h. During the conversion to HBeAg, HBcAg activity was destroyed, as measured both by ID (Fig. 1) and by RIA. Secondly, the relationship between the core and e antigenic specificities was examined. None of the monoclonal anti-HBe preparations was able to inhibit, singly or in mixtures, the binding of polyclonal human anti-HBc (prepared from an HBeAg-positive HBsAg carrier) to HBcAg. Since monoelonal anti-HBc has been shown to cause quite marked inhibition of binding of ~25 I_ labelled polyclonal anti-HBc to HBcAg (Tedder et al., 1983) , this suggested that there was no major cross-reactivity between these two antigens. Also, no preparation of monoclonal or polyclonal anti-HBc inhibited the binding of monoclonal anti-HBe to HBeAg. Taken together, these data indicate that there was little or no similarity between the e and core epitopes, although all were expressed by the core gene product.
Molecular size of serum HBeAg
HBeAg of low molecular weight was prepared from human serum by gel filtration under dissociating conditions in 3 M-KCNS. This material had an apparent mol. wt. of 30 x 103 to 35 × 103 and it also reacted in the monoclonal assay. When the serum containing HBeAg was fractionated under non-dissociating conditions, the bulk of HBeAg was detected with an apparent tool. wt. of between 2 × l0 s and 3 × 10 s. DISCUSSION Initial experiments with BALB/c mice were unsuccessful and it seems that the use of the SJL strain may have been instrumental in producing successful fusions. Although human lymphocytes have been stimulated in vitro to secrete anti-HBe (Furuya et al., 1982) characterization of the anti-HBe reactivities has only been possible with the higher-yielding murine hybridomas. Imai et al. (1982) , using highly purified serum HBeAg, raised a small panel of monoclonal antibodies that differentiated between two different sites on the HBeAg polypeptide, which they referred to as the a and b epitopes. They initially divided their panel into two groups on the ability of mixtures, and not of single clones, to precipitate HBeAg in gel. Antibodies from both groups had to be present for precipitation to occur. Also, antibodies of both specificities had to be present in solid-phase assays for HBeAg. In this study we report similar findings for the detection of HBeAg in solid-phase RIA. However, since we were unable to detect precipitation of monoclonal anti-HBe in gel, we have based the characterization of the monoclonal antibodies on cross-competition experiments.
Initially, hybridomas were screened for anti-HBe activity using antigen from denatured core. It would not be possible to exclude entirely residual HBcAg and for this reason they were retested separately using both denatured HBcAg and serum HBeAg. It is very unlikely that serum from a carrier containing HBeAg would also contain free HBcAg, because of the presence in the serum of excess anti-HBc. Thus, it was considered that the increased binding of 125i_anti_HB e in the capture assay (Table l) truly indicated secretion of anti-HBe by the hybridomas. In spite of having been raised against denatured core they recognized both core-derived HBeAg and also serum HBeAg. We did not find any hybridoma antibody that would react with core-derived HBeAg only. This would indicate that the two peptide species, that of serum HBeAg and liver HBcAg, carried a similar if not identical complement of antigens. Our data, agreeing with those of Imai et aL (1982) , indicated that serum HBeAg carries at least two determinants. Since we could not define the sites as a and b, we elected tO call them e-e and e-fl, and the monoclonal antibodies described here were in turn defined by their reactivity with these sites (Table 2) . It was not possible with a relatively small panel to define precisely to what extent the e-~ and e-fl epitopes represented all available sites expressed on HBeAg. However, although single monoclonal antibodies were inefficient at inhibiting binding of polyclonal human anti-HBe, mixtures of both ~ and fl specificities did inhibit the greater part of the polyclonal label binding. This suggested that, if not representing the entirety of HBeAg epitopes, the c~ and fl sites were likely to be the dominant antigens recognized by mice and men alike.
The close relationship between the core and e antigen was further underlined by the experiments with denatured core antigen. It seemed that the P22 core polypeptide was able to express both e and core antigenic determinants as a function of its physical state and perhaps its degree of polymerization. Certainly the antigenic determinants of both HBeAg and HBcAg were expressed on the P22 polypeptide since the E. coli cloned core material released HBeAg. The generation of HBeAg from HBcAg in these experiments did not require enzymic digestion, and the absence of reducing agents did not diminish the efficiency of conversion. Thus, it seemed that the conformation leading to expression of HBcAg and masking of HBeAg was not stable and was disrupted fairly quickly by the addition of detergent. A similar transition of antigens has been described for polioviruses (Le Bouvier et al., 1957) . This comparison may not be strictly analogous, since whereas the core particle consists of a single polypeptide, the poliovirus consists of four. Nevertheless, it merits some discussion. In polioviruses, the integrity of certain conformational antigens borne on the virus particle depended upon the packing of the capsid units which in turn was influenced by nucleic acid. The density of the E. col#derived HBcAg in CsCI gradients (1.34 g/ml) suggested the presence of nucleic acid, and this has been confirmed by spectroscopy (K. Murray, personal communication). Thus, it may be that the packing of P22 into cores was stabilized, or at least influenced by, the nucleic acid contained both in liver and E. col#cloned cores. This influence may have been mediated by the C' terminal protamine-like sequence of P22. Destabilization by detergent led to conversion of HBcAg to HBeAg and the release of nucleic acid and, subsequently, in the absence of the nucleic acid the P22 would be unlikely to re-polymerize into intact cores.
In serum, HBeAg was present in the molecular weight range of 200000 to 300000. Under dissociating conditions, this was converted into material of around 35000 mol. wt. Native HBeAg of similar molecular size has been found in certain sera (Tedder & Bull, 1979) . It remains a puzzle that a polypeptide of tool. wt. 22 000, which itself carries the two antigenic determinants of HBeAg, may be present in serum with an apparent molecular size of 250 000 and yet behaves in solid-phase RIA as if carrying only single e-a and e-fl antigen sites. Two explanations are considered.
The first is that the HBeAg polypeptide is carried in serum on another serum protein. It has been suggested that this could be an immunoglobulin (Takahashi et al., 1978 (Takahashi et al., , 1983 . A single IgG molecule carrying a P22 molecule would be insufficient to give the observed molecular weight. The second explanation is that P22 polymerizes. In order for a P22 polymer to behave in the observed way, only a single e-a and e-fl determinant can be exposed. This suggests that the and fl sites are involved in the polymerization and become masked by their mutual interaction. A combination of polymerization and interaction with other serum proteins may explain the heterogeneity of serum HBeAg.
On a more practical side, the reagents described in this report will allow demonstration of the site of e antigen synthesis in hepatocytes in liver biopsy material. This has so far been hampered by the difficulty of finding a suitable human serum containing high levels of anti-HBe and low levels of anti-HBc. Another advantage is the high specific binding in solid-phase RIA shown by i25I-labelled monoclonal anti-HBe immunoglobulin (Table 4) . When used in conjunction with complementary antibodies this provided a sensitive RIA which appeared to detect reliably HBeAg and anti-HBe in diagnostic sera (Table 5 ). Further work with this assay needs to be undertaken to confirm these findings, but if the preliminary results are borne out, it seems likely that a new generation of immunoassays for HBeAg will become available which have the higher specific binding normally associated with current assays for HBsAg.
Finally, monoclonal reagents against HBeAg may shed some light upon the multiple reactivities of HBeAg in gel diffusion. There are thought to be three components of the e precipitation complex (Trepo et al., 1978) . If all these reactivities are shown to be associated with HBeAg, it is difficult to see how, with only two major determinants carried on each molecule, this multiplicity of lines can be the result of antigenic heterogeneity alone. It has been suggested previously that heterogeneity of molecular size may cause splitting of HBe/anti-HBe immunoprecipitins (Tedder & Bull, 1979) . Perhaps a combination of size heterogeneity of antigen and a different balance of anti-e-or and anti-e-fl antibodies in sera containing precipitating anti-HBe might be an explanation of the multiple reactivities seen in this complex immunoprecipitation system.
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